Drug Trial Radar · NCT03964493
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Apr 20, 2019
Primary completion
Sep 28, 2020
Study completion Sep 28, 2020
Sponsor
- Lead sponsor
- TenNor Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Gram-Positive Bacterial Infections
Interventions
TNP-2092Drug
TNP-2092 100mg/vial
VancomycinDrug
Vancomycin 1g/vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment
- Early Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment
- Early Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
eStudy Site
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.